Overview

To Study GSP 301 in Patients With Seasonal Allergic Rhinitis

Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
Study to evaluate the two different strengths and dose regimen of GSP 301 to be effective in treatment of seasonal allergic rhinitis.
Phase:
Phase 2
Details
Lead Sponsor:
Glenmark Pharmaceuticals Ltd. India
Treatments:
Mometasone Furoate
Olopatadine Hydrochloride